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Microbiological quality of some brands of intravenous fluids produced by some pharmaceutical 
companies in Nigeria was investigated. Membrane filtration method was used for concentration of 
contaminating organisms in the intravenous fluids. Thioglycollate medium, Tryptone Soya broth, 
Brilliant Green Agar, Pseudomonas medium, Mannitol salt agar, MacConkey agar, and Nutrient agar and 
Saboraud dextrose agar were the media used for the isolation and differentiation of the microbial 
species. Rabbitory method was used for Pyrogen test. Out of 160 samples analyzed, 14 (8.25%) were 
contaminated and remaining 146 (91.75%) were found sterile. The result of pyrogen test showed that 58 
(36.25%) of the samples were pyrogenic. Dextrose (5%), peritoneal dialysis and Normal saline were free 
of detectable microbial species. Contaminating organisms in Dextrose Saline are Microsporum fulvum 
and Aspergillus sp. In Half strength Darrow’s Bacillus cereus, Klebsiella pneumoniae and Aspergillus 
sp. were detected. In Half strength Darrow’s, Full strength Darrow’s and Ringer Lactate, the 
contaminating bacterial species include K. pneumoniae, M. fulvum, Aspergillus sp. and Penicillium sp.  
 





Intravenous administration of fluids, drugs and nutrition is 
very common in hospitals (Waitt et al., 2004). In modern 
medical practice, up to 80% of hospitalized patients 
receive intravenous therapy at some points during their 
admission (Tjon and Ansani, 2000; Tager et al., 1983). 
These important life saving fluids have been reported as 
sources of life threa-tening infections and in some cases 
had been incrimi-nated as one of the strongest factors for 
morbidity and mortality associated with nosocomial 
infections in hospi-tals all over the world. 
In United States, contaminated fluids was found to be 
the largest and most lethal known cause of outbreak of 
nosocomial infections, associated with wide spread distri-
bution of contaminated medical product (Dennis et al., 
1974). Between October, 1970 and March, 1971, eight 
United States Hospitals in seven states experienced 150  
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bacteremias caused by Enterobacter cloacae; there were 
nine deaths and all were associated with intravenous fluid 
therapy (CDC, 1997). 
Nigeria is not an exception; there have been reported 
cases of circulation of contaminated intravenous fluids in 
hospitals in Nigeria. Some deaths and diseases condi-
tions have been attributed to use of these microbiolo-
gically unfit fluids. The Nigerian National Agency for 
Food, Drug Administration and Control (NAFDAC), have 
on many occasions ordered some intravenous fluids 
producing pharmaceutical companies to withdraw their 
products from market and stop further circulation of such 
products on account of microbiological defect. For 
instance, in a nation wide survey of intravenous products 
by NAFDAC in 2004, 566 samples comprised of 42 
products from 8 manufacturers were tested for their 
microbiological fitness, 9 out of 42 products failed 
microbiological and pyrogen tests which are critical para-
meters for the safety of such products. The products 
affected  were   Dextrose  5%,  Dextrose  4.3%  in  0.18% 




Table 1. Microbial contamination level of brand of intravenous fluids produced by some 
pharmaceutical companies in Nigeria. 
 
Products No. tested No. contaminated (%) No. sterile (%) 
Normal saline 20 0 (0.0) 20 (100.0) 
Dexrose 5% 20 0 (0.0) 20 (100.0) 
Dexrose 5% + 0.9% NaCl 20 2 (10.0) 18 (90.0) 
Dexrose 5% + 0.43% NaCl 20 4 (20.0) 16 (80.0) 
Ringer Lactate 20 2 (10.0) 18 (90.0) 
Half strength Darrow’s 20 4 (20.0) 16 (80.0) 
Full strength Darrow’s 20 2 (10.0) 18 (90.0) 
Peritoneal Dialysis solution 20 0 (0.0) 20 (100.0) 




NaCl, Darrow’s half strength and Dextrose 50%. 
Immediate withdrawal of these declared contaminated 
products was ordered by NAFDAC.  
Microbiological specification for intravenous fluids is 
that it must be sterile and pyrogen free throughout it 
shelf-life (European Pharmacopoeia, 2000). Reported 
cases of morbidity and mortality associated with use of 
intravenous are indications that these specifications are 
probably not met. The aim of this research therefore is to 
establish microbiological fitness of some of these intrave-




MATERIALS AND METHODS 
 
Media used and preparation 
 
The media used for the microbiological analysis include, Nutrient 
Agar, Brilliant Green Agar, MacConkey Agar, Saboraude Dextrose 
Agar, Mannitol Salt agar, Tryptone Soya Broth and Thioglycollate 






Random samples of different brands of intravenous fluids produced 
by some notable pharmaceutical companies in Nigeria were purch-
ased at different pharmaceutical stores in Ilorin and Zaria. 20 units 
of the following types of intravenous fluids were bought; 5% dex-
trose (500 ml), 5% dextrose in 0.9% NaCl (dextrose saline, 500 ml), 
5% dextrose in 0.43% NaCl (500 ml), Half strength Darrow’s (500 
ml), Full strength Darrow’s (500 ml), Peritoneal Dialysis (1000 ml), 





Membrane filtration method was used for the analysis. Two hund-
red milliliters (200 ml) was aseptically withdrawn from each unit of 
the samples, and filtered through a 0.45 µm (pore size) Millipore 
filter membrane. The membrane was aseptically removed from the 
filtration unit by using sterile forceps, cut into two parts and dropped 
the first part in Thioglycollate broth and the second part in Tryptone 
soya broth. The thioglycollate broth was incubated at 37oC while the 
Tryptone soya broth was incubated at room temperature for seven 
days. The set up was observed on daily bases for visible turbidity 
that indicate microbial growth. 
Any one with visible growth was removed and subculture into 
solid media for differentiation and characterization. All isolates were 





The test was carried out by following procedures in British Pharma-
copoeia (BP, 1993). Three rabbits which weighed not less than 1.5 
kg each and already conditioned in the environment where the test 
was to be carried out, 2 days before the test, were used for each 
product. Before the injection of the product, Initial temperature of 
each rabbit was determined by taken the mean of two temperature 
difference and recorded. The sample was warmed to 38.5oC before 
injection, and then appropriately diluted with pyrogen free isotonic 
sodium chloride solution. The product was then slowly injected into 
the marginal vein of the ear of each rabbit. The amount of sample 
injected varied; it depends on the type of product examined. The 
temperature of each injected rabbit was taken at interval of 30 min. 
The maximum temperature of each rabbit is the highest tempera-
ture recorded for the rabbit in 3 h after injection. The difference 
between the initial temperature and the maximum temperature of 
each rabbit is taken as its response. Where this difference was 
negative, the result was considered as zero response.  
 
 
RESULTS AND DISSCUSION 
 
A total of one-hundred and sixty (160) samples of intrave-
nous fluids were analysed; fourteen (14) of these sam-
ples (8.75%) were microbiologically contaminated (Table 
1) and one-hundred and fourty-six (146), representing 
91.25% were sterile. Two bacterial and three fungal 
species isolated include Bacillus cereus, Klebsiella 
pneumoniae, Cryptococcus fulvum, Aspergillus spp. and 
Penicillium spp. (Table 2). 
The result of pyrogen test showed that 58(36.25%) out 
of 160 samples analysed for pyrogen were positive, while 
102 (63.75%) were negative for pyrogen (Table 3). 
Dexrose 5% + 0.43% NaCl was more pyrogenic, with 
50% of the samples showed positive for pyrogen. Follow-
ed by Ringer Lactate and Full Strength Darrow’s with 
45% of the samples showing positive for pyrogen. The 
least pyrogenic product  was  Normal  saline  which  gave 




Table 2. Microbial contaminants isolated from brands of intravenous fluids produced by some pharmaceutical 
companies in Nigeria. 
 
Products Microbial contaminants 
D5 DS NS HSD FD RL PD D5% + 0.43% NaCl 
Bacillus cereus - - - + + + - - 
Klebsiella pneumoniae - - - + - - - + 
Micrococcus fulvum - + - - + + - + 
Aspergillus spp. - + - + + - - + 
Penicillium spp. - - - - - - - + 
 
+ = Present; - = Absent; D5 = Dextrose 5%; DS = Dextrose Saline; NS = Normal Saline; HDS = Half Strength Darrow’s; 




Table 3. Pyrogenicity level of some brands of intravenous fluids produced by some pharmaceu-
tical companies in Nigeria. 
 
Products No. tested No. Pyrogenic (%) 
Response > 2.65 
No. Apyrogen (%) 
Normal saline 20 3 ( (15.0) 17 (85.0) 
Dexrose 5% 20 5 (25.0) 15 (75) 
Dexrose 5% + 0.9% NaCl 20 7 (35.0) 13 (65) 
Dexrose5% + 0.43% NaCl 20 10 (50.0) 10 (50.0) 
Ringer Lactate 20 9 (45.0) 11 (55.0) 
Half strength Darrow’s 20 8 (40.0) 12 (60.0) 
Full strength Darrow’s 20 9 (45.0) 11 (55.0) 
Peritoneal Dialysis solution 20 7 (35.0) 13 (65.0) 
Total 160 58 (36.25) 102 (63.75) 
 
 
pyrogenicity level of 15%. 
Intravenous fluids are pharmaceutical products that are 
administered intravenously. Because of the rout of the 
administration, specification for any intravenous product 
is that, they must be sterile and pyrogen-fee. The need 
for sterility of the product arise because, presence of any 
living microorganism in the product meant to be passed 
into the blood stream could result in septicaemia and 
consequently blood stream infections. Several reports in 
the last decade have adduced cases of septicaemia to 
use of intravenous fluids (Twum-Danso et al., 1989; Ng et 
al., 1989; Bin-Ibrahim and Ghaznawi, 1990; Robert et al., 
1990; Lacey and Want, 1991; Frean et al., 1994). 
Contamination level as high as 8.75% (Table 1) in pro-
ducts that suppose to be sterile is alarming and calls for 
overhauling of the production system by the pharmaceu-
tical companies concerned. K. pneumoniae, B. cereus 
and Aspergillus sp. (Table 2) are nosocomial pathogens; 
their presence in the product could result to intrinsic 
nosocomial blood stream infection. Nosocomial blood 
stream infections have been found to a cause of death in 
United State, with mortality rate of 15% (Richard and 
Michael, 2001). Pyrogenicity level of 36.25% (Table 3) 
are rather too high; the reason for this may be attributed 
to contamination level of the products since, pyrogen is 
an endotoxin produced by some microorganisms especi-
ally gram-negative organisms. Infusion of pyrogenic 
product into already debilitated patients could only wors-
en the patients’ condition and decrease their chances of 
survival.  
From the above results it can be concluded that micro-
biological unfit products, supplied to the hospitals by the 
manufacturers, are significant factor that must not be 
over looked. Certificate of analysis of every batch of the 
product supplied must be demanded from the manufactu-
rers to ensure that the batch has been properly 





Bin-Ibrahim A, Ghaznawi HI (1990). Nosocomial spread of K. 
pneumoniae  through contaminated intravenous fluids. Proceeding 
from 2nd International Confrence of the Hospital infection Society, 
London. 
Centre for Disease Control (CDC) (1997). Epidemiologic notes and 
reports nosocomial bacteremias associated with Intravenous Fluids 
therapy-USA. MMWR: 46(51): 1227–1233.  
Dennis GM, Roger LA, Jones AS (1974). In- use contamination of 
intravenous fluids. Appl. Microbiol. pp. 778-784. 
Frean JA, Arntezen L, Rosekilly I, Isaacson M (1994). Investigation of 
contaminated parenteral nutrition fluids associated with an out break 
of Serratia odorifera. Septicaemia. J. Hosp. Infest. 27: 263-273.  
Lacey S, Want SV (1991). Pseudomonas pickettii infections in 
paediatric ancology unit. J. Hosp. infect. 17: 45–51. 
Ng PC, Herington RA, Beanc CD, Ghoneim ATM, Dear PRF (1989). An 




out break of Acinectobactr septicaemia in neonatal intensive care 
unit. J. Hosp. infest. 14: 363–368. 
Richard PW, Michael BE (2001). The impact of Hospital-Acquired 
Bloodstream Infections. Emerg. Infect. Dis. 7(2): 174–177. 
Robert LA, Collignon PJ, Cramp VB (1990). Australian wide epidemic of 
Pseudomonas pickettii, bacteremia due to contaminated sterile water 
for injection. Med. J. Austr. 152: 652-655. 
Tager IB, Ginsberg MB, Ellis SE (1983). An epidemiologic study of the 
risk associated with peripheral intravenous catheter. Am. J. 



































































Tjon JA, Ansani NT (2000). Transdermal nitroglycerin for the prevention 
of intravenou Infusion failure due to phlebitis and extravasation. Ann. 
Pharmacother., 34: 1188 –1192. 
Twum-Danso K, Dawodu AH, Saleh MAF, Makiling LS (1989). An out 
break of K. pneumoniae bacteremia in five children on intravenous 
therapy. J. Hosp. Infest. 14: 271–274. 
Waitt C, Waitt C, Pirmohamed M (2004). Intravenous therapy. PGD 
Med. J. 80: 1-6. 
